---
title: "Weekly Recap | Zoetis -0.49%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300193168.md"
description: "Zoetis (ZTS) fell 0.49% this week to close at $71.05, while the S&P 500 rose 1.21%, putting the stock about 1.7 percentage points behind the benchmark. The week ran up then faded: Monday (Sep 21) opened at $72.06, Tuesday (Sep 22) pushed to $72.86 before pulling back, Wednesday (Sep 23) touched a high of $73.55, then the final two sessions softened. Friday (Sep 25) dipped to $69.52 before ending at $71.05. Weekly amplitude was 5.59%, and the latest quote sits just above the close."
datetime: "2026-09-26T07:23:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300193168.md)
  - [en](https://longbridge.com/en/news/300193168.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300193168.md)
generator: "portal-rs"
---

# Weekly Recap | Zoetis -0.49%, consensus target above spot

## The Week

Zoetis (ZTS) fell 0.49% this week to close at $71.05, while the S&P 500 rose 1.21%, putting the stock about 1.7 percentage points behind the benchmark. The week ran up then faded: Monday (Sep 21) opened at $72.06, Tuesday (Sep 22) pushed to $72.86 before pulling back, Wednesday (Sep 23) touched a high of $73.55, then the final two sessions softened. Friday (Sep 25) dipped to $69.52 before ending at $71.05. Weekly amplitude was 5.59%, and the latest quote sits just above the close.

## Key Events

Position updates and the Q3 earnings schedule dominated the headlines. On Monday (Sep 21), Nykredit established a new holding; on Tuesday (Sep 22), a note asked whether Zoetis was still 23% below fair value. Thursday (Sep 24) brought a flash that the stock outperformed competitors despite losing ground on the day, and the company confirmed it will host its fiscal Q3 2026 webcast and call on 5 November before the open. The week’s narrative centred on positioning shifts ahead of the next earnings report.

## Analyst Ratings

Across 17 brokers covering Zoetis, 4 rate it buy, 4 overweight, and 9 hold, with no underweight or sell ratings. Consensus is buy, with a target of $96, or 35.12% above the latest price. Targets range from $80 to $155, a wide spread. Within the pharma industry, Zoetis ranks 10th out of 203 names.

## The Week Ahead

The macro calendar is dense next week: Tuesday (Sep 29) includes JOLTS job openings, consumer confidence, FHFA home prices and the Case Shiller 20-city index. For Zoetis itself, the key date is 5 November pre-market results, with consensus EPS of $1.41 and revenue of $2.298 billion. Next week’s action likely tracks macro prints and animal-health peers rather than company news.

## In Short

Zoetis lagged the market this week, trading between $69.52 and $73.55 and closing at $71.05. The sell-side leans positive: consensus is buy and the target sits 35% above spot, though the $80–$155 range signals wide disagreement. Valuation shows an 11.13x P/E and 9.33x P/B, and the latest session’s large- and medium-lot flows both pointed net buying, as did retail. The tension now sits on whether Q3 results can validate current expectations and how macro data shifts risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ZTS.US](https://longbridge.com/en/quote/ZTS.US.md)

## Related News & Research

- [Zoetis Inc. $ZTS Stock Holdings Increased by Moran Wealth Management LLC](https://longbridge.com/en/news/296020852.md)
- [Zoetis' (ZTS) Market Perform Rating Reaffirmed at William Blair](https://longbridge.com/en/news/295128765.md)
- [Marin Bay Wealth Advisors LLC Buys 5,710 Shares of RTX Corporation $RTX](https://longbridge.com/en/news/303855185.md)
- [Sumitomo Mitsui Trust Group Inc. Sells 30,195 Shares of GE Vernova Inc. $GEV](https://longbridge.com/en/news/303856773.md)
- [Invera Wealth Advisors LLC Makes New Investment in NXP Semiconductors N.V. $NXPI](https://longbridge.com/en/news/303855332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**